RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.
Integrated analysis of public transcriptomic datasets identify an RBCK1-HLTF-JAK2/STAT3 regulatory axis that promotes cisplatin resistance in bladder cancer cells, and xenograft validation further supports the role of RBCK1 depletion in enhancing cisplatin response in vivo.